T. Rowe Price Associates, Inc. 13D and 13G filings for ACADIA Pharmaceuticals Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 12:38 pm Sale | 2022-12-31 | 13G | ACADIA Pharmaceuticals Inc. ACAD | T. Rowe Price Associates, Inc. | 4,279,254 2.600% | -5,207,007 (-54.89%) | Filing |
| 2022-02-14 2:34 pm Purchase | 2021-12-31 | 13G | ACADIA Pharmaceuticals Inc. ACAD | T. Rowe Price Associates, Inc. | 9,486,261 5.900% | 1,608,436 (+20.42%) | Filing |
| 2021-02-16 12:23 pm Sale | 2020-12-31 | 13G | ACADIA Pharmaceuticals Inc. ACAD | T. Rowe Price Associates, Inc. | 7,877,825 4.900% | -5,363,189 (-40.50%) | Filing |